COYA Earnings Date: Nov 11, 2026 (Estimated) — Coya Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is COYA's next earnings date?
Coya Therapeutics, Inc. (COYA) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.35 on revenue of $110,000.
How did COYA do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Coya Therapeutics, Inc. posted EPS of -$0.28 versus the -$0.35 estimate, a beat of 22.2%. Revenue was $243,745 against a $130,000 estimate. The stock's 1-day post-earnings move was +3.4%.
How much does COYA stock move after earnings?
COYA beat EPS estimates in 3 of its last 6 reported quarters. Over the last 8 reports the stock moved an average of 3.7% (up or down) in the day after earnings.
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.35 | -0.28 | +22.22% | $243,745 | ✅ Beat | +3.45% | +0.65% | -0.65% |
| 2026-05-12 | Q1 2026 | -0.39 | -0.32 | +17.95% | $251,147 | ✅ Beat | +2.63% | +17.70% | +5.50% |
| 2026-03-16 | Q4 2025 | -0.21 | -0.34 | -61.90% | $4.0M | ❌ Miss | -0.66% | -7.06% | -1.55% |
| 2025-11-12 | Q3 2025 | -0.17 | -0.13 | +23.53% | $3.6M | ✅ Beat | +1.33% | +2.50% | +3.99% |
| 2025-08-12 | Q2 2025 | -0.35 | -0.36 | -2.86% | $163,616 | ❌ Miss | -0.33% | -2.28% | +2.60% |
| 2025-03-18 | Q4 2024 | — | -0.18 | — | $2.0M | — | -5.84% | -2.92% | -19.56% |
| 2024-08-12 | Q2 2024 | -0.14 | -0.19 | -35.71% | $3.4M | ❌ Miss | -12.87% | -15.51% | -4.29% |
| 2024-03-19 | Q4 2023 | — | 0.15 | — | $6.0M | — | +2.13% | -10.14% | -16.43% |
Showing last 8 quarters.